NewAmsterdam Pharma Company N.V. (NAMS)

Over the past six months, NewAmsterdam Pharma's stock price has increased. The company announced an upsized public offering in December 2024, which led to a slight stock decline. Third quarter 2025 financial results showed decreased revenue and increased net loss compared to 2024. Marketing Authorization Applications for obicetrapib were accepted by the EMA. Clinical data from trials were published. Inducement share options grants were reported. Leerink Partners raised its price target for NewAmsterdam Pharma.

NewAmsterdam Pharma Co. NV does not currently experience demand seasonality for its products and services, as it is a clinical-stage biopharmaceutical company with its primary product still under development.

NewAmsterdam Pharma Co. NV is a biopharmaceutical company focused on metabolic diseases with unmet needs. Their main product, obicetrapib, is a CETP inhibitor in development for lowering LDL-C and is also being studied for Alzheimer's disease.

NewAmsterdam Pharma Co. NV is headquartered in Naarden, Netherlands, and Aventura, Florida, USA. They have a licensing agreement with the Menarini Group for commercialization of obicetrapib in Europe.

NewAmsterdam Pharma's brand reputation has been positively influenced by positive topline results from the Phase 3 BROADWAY trial and the acceptance of Marketing Authorization Applications by the European Medicines Agency. Analyst sentiment is generally positive, with a consensus rating of "Moderate Buy". MarketBeat ranked NewAmsterdam Pharma higher than 69% of companies evaluated in the medical sector.

NewAmsterdam Pharma Co. NV has a significant institutional ownership base. Insider ownership stands at 20.84%. Insiders have purchased shares for $784,830.73 and sold shares for $39,306,784.12 in the past 24 months.